Online Class Incremental Learning on Stochastic Blurry Task Boundary via Mask and Visual Prompt Tuning

Continual learning aims to learn a model from a continuous stream of data, but it mainly assumes a fixed number of data and tasks with clear task boundaries. However, in real-world scenarios, the number of input data and tasks is constantly changing in a statistical way, not a static way. Although recently introduced incremental learning scenarios having blurry task boundaries somewhat address the above issues, they still do not fully reflect the statistical properties of real-world situations because of the fixed ratio of disjoint and blurry samples. In this paper, we propose a new Stochastic incremental Blurry task boundary scenario, called Si-Blurry, which reflects the stochastic properties of the real-world. We find that there are two major challenges in the Si-Blurry scenario: (1) inter- and intra-task forgettings and (2) class imbalance problem. To alleviate them, we introduce Mask and Visual Prompt tuning (MVP). In MVP, to address the inter- and intra-task forgetting issues, we propose a novel instance-wise logit masking and contrastive visual prompt tuning loss. Both of them help our model discern the classes to be learned in the current batch. It results in consolidating the previous knowledge. In addition, to alleviate the class imbalance problem, we introduce a new gradient similarity-based focal loss and adaptive feature scaling to ease overfitting to the major classes and underfitting to the minor classes. Extensive experiments show that our proposed MVP significantly outperforms the existing state-of-the-art methods in our challenging Si-Blurry scenario

Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction with Idiopathic Thrombocytopenic Purpura: A Case Report

Acute myocardial infarction (AMI) is rare in patients with idiopathic thrombocytopenic purpura (ITP). We describe a case of an AMI during thrombocytopenia in a patient with chronic ITP. A 47-yr-old woman presented with anterior chest pain and a low platelet count (21,000/µL) at admission. Urgent coronary angiography revealed total occlusion of proximal right coronary artery and primary percutaneous coronary intervention (PCI) was performed successfully. This case suggests that primary PCI may be a therapeutic option for an AMI in patients with ITP, even though the patient had severe thrombocytopenia

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

BACKGROUND: The aim of this study was to examine the efficacy and safety of everolimus in patients with progressive unresectable adenoid cystic carcinoma (ACC). METHODS: Histologically confirmed ACC patients with documented disease progression within 12 months prior to the study entry were eligible. Everolimus was given at a dose of 10 mg daily until progression or occurrence of unacceptable toxicities. The primary endpoint was a 4-month progression-free survival (PFS). RESULTS: A total of 34 patients were enrolled. The 4-month PFS probability was 65.5% (95% one-sided confidence interval [CI], 47.7 to infinity). Median PFS duration was 11.2 months (95% CI, 3.6 to 15.8). Complete or partial response was not achieved. Twenty-seven (79.4%, 95% CI, 63.2 to 89.6) patients showed stable disease (SD). Tumor shrinkage within SD criteria was observed in 15 patients (44.1%) and SD lasting 6 months was observed in 13 patients (38.2%). Four patients had disease progression. Among the 18 patients with both pre- and post-treatment (at 8 weeks) FDG-PET scans available, 8 patients (44.4%) showed a partial metabolic response, defined as a ≥25% reduction in maximum standardized uptake values (SUVmax). The most common adverse events were stomatitis, anemia, asthenia, and leukopenia. No unexpected everolimus related toxicities were reported. CONCLUSIONS: Everolimus showed promising efficacy and good tolerability in progressive unresectable ACC. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT0115284